What is the FDA recommended regimen of reteplase for thrombolytic therapy of pulmonary embolism (PE)?

Updated: Aug 04, 2021
  • Author: Wanda L Rivera-Bou, MD, FAAEM, FACEP; Chief Editor: Erik D Schraga, MD  more...
  • Print


Reteplase has not been approved by the FDA for any indication except AMI, but it is widely used for acute deep vein thrombosis (DVT) and PE. The dosing used is the same as that approved for patients with AMI: two IV boluses of 10 U each, administered 30 minutes apart.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!